With the rapid advances in biotechnology and the widespread availability and popularity of assisted reproductive technologies, biologists may soon have the ability to manipulate human gametes and embryos in order to create children with certain desirable characteristics. Despite the fact that this scientific idea is closer to becoming a reality, the question remains whether such techniques or the altered genetic material itself are eligible for patents. After the Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics, Inc., — US. —, 133 S. Ct. 2107 (2013), the court held that isolated DNA was not the proper subject matter for patent under 35 U.S.C. § 101, while holding a patent on synthetic DNA, or “cDNA.” This article argues for a narrow reading of the holding in Myriad Genetics regarding cDNA, which would limit its application to the medical uses and gene therapy.